Richard Federspiel, MD
Dermatology · West Lafayette, INNPI 1649342817
Payments from drug & device makers
Across 92 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$662
- Johnson & Johnson$325
- Novartis$91
- Sun Pharmaceutical Industries Inc.$74
- UCB, Inc.$70
- Merck$24
- plus $126 from 8 others
What the payments were for
- Food & beverage$1,12782%
- Education$24518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $662 |
| Johnson & Johnson | 10 | $325 |
| Novartis | 7 | $91 |
| Sun Pharmaceutical Industries Inc. | 5 | $74 |
| UCB, Inc. | 3 | $70 |
| Merck | 2 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Amgen | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| GSK | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Dermira, Inc. | 1 | $12 |
| Novo Nordisk | 1 | $11 |
How this compares
$1,371 in reported general payments places this provider in the 30th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $82,167 |
| Clobetasol Propionate | 105 | $6,774 |
| Fluocinonide | 133 | $5,424 |
| Metronidazole | 92 | $4,921 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 79 | $3,340 |
| Fluocinonide-EFluocinonide/Emollient Base | 51 | $2,654 |
| Doxycycline Hyclate | 81 | $2,263 |
| Doxycycline Monohydrate | 70 | $2,219 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 52 | $1,315 |
| Azelaic Acid | 18 | $963 |
| Triamcinolone Acetonide | 60 | $963 |
| Mometasone Furoate | 58 | $903 |
| MethotrexateMethotrexate Sodium | 35 | $849 |
| Ammonium Lactate | 46 | $817 |
| Minocycline Hcl | 18 | $578 |
Paid to pharmacies, not to this prescriber.
Other dermatology in West Lafayette
- Scott GuenthnerPlainfield$10.7M
- Scott FretzinIndianapolis$9.8M
- David RosmarinIndianapolis$4.4M
- Holly Hake HarrisSouth Bend$3.4M
- Megan LandisCorydon$2.8M
- Kenneth DawesIndianapolis$2.2M
- Ginat MirowskiIndianapolis$1.8M
- Vassilios DimitropoulosMichigan City$1.8M
- Christopher ObeimeIndianapolis$907K
- Megan VissingNew Albany$884K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.